Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-labelled Claudin 18.2 PET/CT in Pancreatic Cancer
NCT07597772Phase 1Recruiting
- Sponsor
- SmartNuclide
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Nanobodies (VHH), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NODAGA-SNA006 in pancreatic cancer (PC), sponsored by SmartNuclide. Primary endpoints: Safety and tolerability profile at 1 week and CLDN18.2-targeting ability at 1 week. Started Oct 2025; status: recruiting.
02
Drugs
68Ga-NODAGA-SNA006
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07597772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597772.